Mitralign company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

mitralign.com

Founded Year

2004

Stage

Series F | Alive

Total Raised

$153.68M

Last Raised

$9.77M | 4 yrs ago

About Mitralign

Mitralign is developing a catheter-based technology for percutaneous treatment of functional mitral regurgitation. The Mitralign system emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.

Mitralign Headquarter Location

3 Highwood Drive

Tewksbury, Massachusetts, 01876,

United States

978-863-2400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Mitralign

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Mitralign is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

7,915 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

Mitralign Patents

Mitralign has filed 46 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac surgery
  • Cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/18/2018

6/29/2021

Actuators, Linear motion, Linkages (mechanical), Medical equipment, Dosage forms

Grant

Application Date

4/18/2018

Grant Date

6/29/2021

Title

Related Topics

Actuators, Linear motion, Linkages (mechanical), Medical equipment, Dosage forms

Status

Grant

Latest Mitralign News

Edwards Lifesciences gets in on Corvia, Mitralign

Mar 11, 2019

MassDevice Edwards Lifesciences gets in on Corvia, Mitralign March 11, 2019 Edwards Lifesciences  (NYSE: EW ) said today that it made a pair of strategic bets on the structural heart space, paying $35 million for the right to acquire Corvia Medical and paying an unspecified amount for some of mitral valve repair device maker Mitralign ‘s assets. Tewksbury, Mass.-based Corvia is developing an interatrial shunt to treat heart failure by creating a small opening between the left and right atria to lower blood pressure in the left atrium and lungs. The device has CE Mark approval in the European Union and a pivotal U.S trial aimed at winning a nod from the FDA is under way, Edwards said. The Irvine, Calif.-based company also said it bought “certain” Mitralign assets, including intellectual property and associated clinical and regulatory experience. Mitralign, also based in Tewksbury, is developing an annuloplasty system for treating functional mitral and tricuspid regurgitation. Edwards said the transactions are not expected to affect its financial outlook for 2019. Women hold more executive leadership roles in the medtech industry today than they did 20 years ago, but there’s still a long way to go. There is still a women’s leadership gap in the U.S., though. According to a report from the Centers for American Progress, women hold 52% of professional jobs in the U.S.… […] FDA said today that it has received more than 41,000 adverse event reports — including 366 deaths — associated with surgical staplers and staples for internal use, and that it may require stricter product review of the devices. The agency’s ongoing analysis of stapler- and internal-staple-related adverse event reports from Jan. 1, 2011 to March… […] Shares in Stratasys (NSDQ:SSYS) rose today after the 3D-printing giant met expectations on Wall Street with its fourth quarter and full year 2018 earnings release. Minneapolis- and Rehovot, Israel-based Stratasys posted profits of $6.3 million, or 12¢ per share, on sales of $177.1 million for the three months ended December 31, seeing a swing from red ink… […] Integrated Computer Solutions announced that it will offer BlackBerry’s QNX software as part of its touch-enabled devices. “Committed to developing high-quality software devices, ICS is pleased to expand our ability to deliver comprehensive solutions by joining the BlackBerry QNX Channel Partner Program,” Peter Winston, CEO of ICS, said in a press release. “Our long history… […] A new study has found that NeurOptics’ NPi-200 pupillometer, which provides an automated assessment of the pupillary light reflex, may give an early warning of delayed cerebral ischemia, enabling preemptive care. The study was published in the Journal of Neurosurgery. The study analyzed 56 patients diagnosed with aneurysmal subarachnoid hemorrhage and admitted to the neuro-intensive… […] A new study will investigate whether Eko’s digital stethoscopes and artificial intelligence (AI) algorithms can interpret heart sounds accurately to help screen for pathologic heart murmurs and valvular heart disease. Eko’s Duo portable cardiac device won FDA clearance in 2017. The hand-held system combines a digital stethoscope with an electrocardiogram to give cardiologists insight into… […] Accenture (NYSE:ACN) has agreed to acquire Enterprise System Partners (ESP), a consulting and manufacturing services provider for the life sciences industry. Headquartered in Cork, Ireland, ESP will join Accenture’s digital manufacturing arm, Industry X.0, to boost Accenture’s efforts to transform manufacturing for pharmaceutical, biotech and medical device clients globally. ESP has long-standing experience in planning… […] The Hahn Group scooped up the IP and trademarks for the Sawyer collaborative robot and Intera software less than one month after Rethink Robotics Inc. shut down in October 2018. The German automation and robotics specialist, which has 30-plus years of automation experience, recently gave The Robot Report an exclusive look at how it plans to revitalize the Sawyer brand around… […] Qosina recently turned to Evonik’s Cryolite G-20 Hiflo acrylic-based copolymer compound to make its own specialized luer lock connector. “Delays in manufacturing were creating issues for us in terms of meeting customer demand in a timely fashion,” Geri Trautman, product development manager at Qosina, said in a March 4 news release. “So, after we started… […] Weiss-Aug recently announced that it has added a Laser Lab Technology Center to its surgical products division in Fairfield, N.J. The new laser-cutting and etching machines expand the company’s ability to meet product development demands. A precision metal-stamping, insert-molding and assembly company, Weiss-Aug said that precision laser cutting is faster, requires shorter setup, can process… […]

  • When was Mitralign founded?

    Mitralign was founded in 2004.

  • Where is Mitralign's headquarters?

    Mitralign's headquarters is located at 3 Highwood Drive, Tewksbury.

  • What is Mitralign's latest funding round?

    Mitralign's latest funding round is Series F.

  • How much did Mitralign raise?

    Mitralign raised a total of $153.68M.

  • Who are the investors of Mitralign?

    Investors of Mitralign include Oxford Bioscience Partners, Forbion Capital Partners, Triathlon Medical Venture Partners, Accelerated Technologies Partners, Horizon Technology Finance and 15 more.

  • Who are Mitralign's competitors?

    Competitors of Mitralign include NeoChord, Ancora Heart, Benvenue Medical, Cardiac Dimensions, Dextera Surgical and 12 more.

You May Also Like

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

Ancora Heart Logo
Ancora Heart

Ancora Heart is developing a therapy to address heart failure. Ancora Heart's AccuCinch Ventricular Repair System is a minimally invasive investigational treatment for heart failure and functional mitral regurgitation (FMR).

Cardiac Dimensions Logo
Cardiac Dimensions

Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Frankfurt, Germany.

Angel Medical Systems Logo
Angel Medical Systems

Angel Medical Systems has developed the AngelMed Guardian system, an implantable cardiac monitoring and alerting system that is designed to warn cardiac patients of potentially life-threatening heart conditions. The AngelMed Guardian System heart monitor is designed to track changes in the heart's electrical signal from a standard pacemaker lead, identify the signature of acute thrombotic occlusions when they occur, and then alert the patient directly to seek medical attention. The device is being studied in high risk heart patients who do not qualify for an ICD, but who have had a STEMI, NSTEMI or unstable angina in their recent past.

C
Cardiac Power

Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure

B
Bio Control Medical

Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.